Allergy Therapeutics plc (AIM:AGY)
London · Delayed Price · Currency is GBP · Price in GBX 5.40
-0.58 (-9.70%)
Jul 27, 2026, 4:35 PM GMT
Allergy Therapeutics Income Statement
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 57.29 | 55.04 | 55.2 | 59.59 | 72.77 | 84.33 | |
Revenue Growth | 4.09% | -0.28% | -7.36% | -18.11% | -13.71% | 7.83% |
Cost of Revenue | 27.38 | 25.74 | 25.46 | 26.34 | 23.26 | 22.11 |
Gross Profit | 29.92 | 29.3 | 29.74 | 33.25 | 49.51 | 62.23 |
Selling, General & Admin | 42 | 39.16 | 38.06 | 48.88 | 46.83 | 45.87 |
Depreciation & Amortization Expenses | 4.4 | 4.17 | 4.32 | - | - | - |
Research & Development | 16.56 | 15.38 | 22.9 | 20.12 | 15.66 | 12.89 |
Other Operating Expenses | -1.06 | -1.24 | -0.29 | 3.89 | -0.74 | -0.57 |
Total Operating Expenses | 61.9 | 57.46 | 64.99 | 72.9 | 61.75 | 58.19 |
Operating Income | -30.93 | -28.16 | -35.26 | -39.65 | -12.25 | 4.03 |
Interest Income | 0.31 | 0.38 | 0.29 | 0.33 | 0.26 | 0.12 |
Interest Expense | -8.15 | -7.17 | -4.19 | -2.44 | -0.67 | -0.49 |
Other Non-Operating Income (Expense) | -5.88 | -4.25 | - | - | - | - |
Total Non-Operating Income (Expense) | -13.72 | -11.04 | -3.91 | -2.11 | -0.41 | -0.37 |
Pretax Income | -47.17 | -39.2 | -39.17 | -41.77 | -12.66 | 3.66 |
Provision for Income Taxes | 1.8 | 0.93 | -0.55 | 1.31 | 1.12 | 0.77 |
Net Income | -48.97 | -40.13 | -38.62 | -43.07 | -13.78 | 2.89 |
Net Income to Common | -48.97 | -40.13 | -38.62 | -43.07 | -13.78 | 2.89 |
Net Income Growth | - | - | - | - | - | -59.11% |
Shares Outstanding (Basic) | 4,996 | 4,766 | 3,743 | 670 | 643 | 639 |
Shares Outstanding (Diluted) | 4,996 | 4,766 | 3,743 | 670 | 643 | 677 |
Shares Change | 4.81% | 27.33% | 458.41% | 4.26% | -4.98% | 0.47% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 |
EPS Growth | - | - | - | - | - | -59.05% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | -36.71 | -31.37 | -35.54 | -33.55 | -17.06 | 6.03 |
Free Cash Flow Growth | - | - | - | - | - | -41.03% |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.05 | -0.03 | 0.01 |
Gross Margin | 52.22% | 53.23% | 53.87% | 55.79% | 68.03% | 73.79% |
Operating Margin | -53.98% | -51.16% | -63.87% | -66.55% | -16.83% | 4.78% |
Profit Margin | -85.46% | -72.91% | -69.97% | -72.28% | -18.93% | 3.42% |
FCF Margin | -64.07% | -57.00% | -64.38% | -56.30% | -23.44% | 7.15% |
EBITDA | -26.53 | -23.99 | -30.94 | -35.43 | -8.08 | 8.16 |
EBITDA Margin | -46.30% | -43.58% | -56.05% | -59.46% | -11.10% | 9.68% |
EBIT | -30.93 | -28.16 | -35.26 | -39.65 | -12.25 | 4.03 |
EBIT Margin | -53.98% | -51.16% | -63.87% | -66.55% | -16.83% | 4.78% |
Effective Tax Rate | -3.81% | -2.38% | 1.39% | -3.12% | -8.84% | 21.08% |